Evaluation of Efficiency of Intravitreal Injection (Bevacizumab) In Treatment of Diabetic Macular Edema
DOI:
https://doi.org/10.65693/irss.2023.v4i1.321Keywords:
Bevacizumab, Diabetic Macular Edema - DME, (Diabetic Retinopathy)Abstract
Background: Anti-VEGF agents have been proven to be effective in treating macular edema secondary to a multitude of pathological conditions. However, in large clinical trial settings, the results may be overstated. This study aimed to evaluate the efficacy of intravitreal injection Bevacizumab in patients with diabetic macular edema in term of detect the improvement of visual acuity, macular edema and thickness according to the ophthalmological parameters [Optical Coherence Tomography (OCT), Visual Acuity (VA) and Best-Corrected Visual Acuity (BCVA)].
Methods: This is a Retrospective, Analytical study was conducted at Magrabi Eye Hospital, Sana’a, Yemen From June 2022 to December 2022. n: 245 eyes of 173 patients with macular edema were treated with intravitreal Bevacizumab injections. Visual Acuity, Best-corrected visual acuity (BCVA), and OCT parameters including central retinal thickness (CRT) were assessed prior to the injections and then 4 weeks post injection and compared. Systematic random sampling method was used. The data were collected from the medical records of the patients. The data analysis was performed on the cleaned datasets using SPSS Software (SPSS inc., Chicago.II.USA, version 25.0).
Result: The study sample consisted of (n: 245) eyes of 173 patients who had treated with intravitreal injection (Bevacizumab), the results showed that there is an improvement in the ophthalmological parameters Optical Coherence Tomography (OCT), Best-Corrected Visual Acuity (BCVA) and visual acuity as the following (75.1%), (71.8) and (55.1), respectively. The results also revealed that there is a statistically significant relationship at the level (p<0.05) between; (OCT before and after treatment), (Baseline VA and VA at last visit) and (Baseline VA and BCVA).
Conclusion: Treatment with intravitreal Bevacizumab injections was found safe and resulted in clinically and statistically significant improvement in OCT parameters and visual acuity in patients with macular oedema secondary to various retinal pathologies.
Keywords: Bevacizumab; Macular Edema; Diabetic Retinopathy; Magrabi Eye Hospital; Sana’a, Yemen.
References
1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab Res Clin Pract. 2014;103(2):137-149.
2. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Bruxelas, Bélgica: International Diabetes Federation; 2015.
3. Cho NH, Shaw JE, Karuranga S, et al. Global estimates of diabetes prevalence for 2017 and projections for 2045. Diab Res Clin Pract. 2018;138:271-281.
4. Dodda D, Ciddi V. Plants used in the management of diabetic complications. Indian J Pharm Sci. 2014;76(2):97-106.
5. Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015;22(2):151-156.
6. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
7. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
8. Mitchell P, Wong TW; Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505-13.
9. Ratner, M. (2004). "Genentech discloses safety concerns over Avastin." Nature Biotechnology 22(10): 1198-1198.
10. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
11. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology 1984; 91: 1464-1474.
12. Wormald R, Smeeth L, Henshaw K. Medical interventions for diabetic retinopathy. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. London: BMJ Books; 2004: 331.
13. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
14. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638-645.
15. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304:649-56.
16. Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26:1731-37.
17. Rema M, Premkumar S, Anitha B, et al. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005:46:2328-33.
18. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011;8:228-36.
19. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116:461-67.
20. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64.
21. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;10(376):124-36.
22. Klein R. The epidemiology of diabetic retinopathy. In: Duh E, editor. Diabetic retinopathy. Totowa: Humana Press; 2008. p. 67-108.
23. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
24. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.
25. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
26. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592-96.
27. Pr Gabriel Coscas Oedemes maculaires Aspects cliniques et therapeutiques, Editura Springer Science & Business Media, 15 sept. 2011, Spain, page 110-196.
28. Oct & Retine dr. Marie Benedicte Rougier, Pr. Marie Noelle Delyfer, Pr. Jean-Francois Korobelnik Centre Hospitalier Universitaire de Bordeaux, Editura: Laboratoire Thea, 12 Rue Louise Bleriote, France, page 33-63.
29. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. American journal of ophthalmology. 1999;127(6):688-693.
30. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular edema. Survey of ophthalmology. 1984;28:505-511.
31. Xu H-Z, Le Y-Z. Significance of outer blood-retina barrier breakdown in diabetes and ischemia. Investigative Ophthalmology & Visual Science. 2011;52(5):2160-2164.
32. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625.
33. Del Zoppo G. The neurovascular unit in the setting of stroke. Journal of internal medicine. 2010;267(2):156-171.
34. Gao B-B, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature medicine. 2007;13(2):181-188.
35. Jeppesen P, Aalkjær C, Bek T. Bradykinin relaxation in small porcine retinal arterioles. Investigative ophthalmology & visual science. 2002;43(6):1891-1896.
36. Parpura V, Basarsky TA, Liu F, et al. Glutamate-mediated astrocyte-neuron signalling. Nature. 1994;369(6483):744-747.
37. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Arch ophthalmol. 1985;103:1796-1806.
38. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-136.
39. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-564.
40. Viswanath K, McGavin DD. Diabetic retinopathy: clinical findings and management. Community Eye Health. 2003;16:21.
41. Diabetic retinopathy - Symptoms and causes. Mayo clinic. 2015.
42. Cantrill HL. The diabetic retinopathy study and the early treatment diabetic retinopathy study.-PubMed-NCBI.
43. Bailey C, Sparrow J, Grey R, et al. The national diabetic retinopathy laser treatment audit. I. Maculopathy. Eye. 1998;12(1):69-76.
44. Bailey C, Sparrow J, Grey R, et al. The national diabetic retinopathy laser treatment audit. I. Maculopathy. Eye. 1998;12(1):69-76.
45. Bailey C, Sparrow J, Grey R, et al. The national diabetic retinopathy laser treatment audit. I. Maculopathy. Eye. 1998;12(1):69-76.
46. Tripathy K, Raj Sharma Y, Chawla R, et al. Recent advances in management of diabetic macular edema. Current diabetes reviews. 2015;11(2):79-97.
47. Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA ophthalmology. 2016;134(8):888-896.
48. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): 12-month data: report 2. Ophthalmology. 2010;117(6):1078-1086. e1072.
49. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359.
50. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351-1359.
51. Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116(8):1488-1497. e1481.
52. Network DRCR. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447-1459. e1410.
53. Boyer DS, Yoon YH, Belfort Jr R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
54. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
55. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustaineddelivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635. e622.
56. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy. Investigative ophthalmology & visual science. 2010;51(4):2135-2138.
57. Simpson AR, Dowell NG, Jackson TL, et al. Measuring the effect of pars plana vitrectomy on vitreous oxygenation using magnetic resonance imaging. Investigative ophthalmology & visual science. 2013;54(3):2028-2034.
58. Sivaprasad S, Ockrim Z, Massaoutis P, et al. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina. 2008;28(10):1435-1442.
59. Stefansson E, Landers 3rd M, Wolbarsht M. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Transactions of the American Ophthalmological Society. 1981;79:307.
60. Stefansson E, Landers 3rd M, Wolbarsht ML. Vitrectomy, lensectomy, and ocular oxygenation. Retina (Philadelphia, Pa.). 1982;2(3):159-166.
61. Stefansson E, Novack R, Hatchell D. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Investigative ophthalmology & visual science. 1990;31(2):284-289.
62. Lee B, Litt M, Buchsbaum G. Rheology of the vitreous body. Part I: viscoelasticity of human vitreous. Biorheology. 1992;29(5-6):521-533.
63. Gandorfer A, Messmer EM, Ulbig MW, et al. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina (Philadelphia, Pa.). 2000;20(2):126-133.
64. Jackson TL, Nicod E, Angelis A, et al. Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Retina. 2017;37(5):886-895.
65. Nakajima T, Roggia MF, Noda Y, et al. Effect of internal limiting membrane peeling during vitrectomy for diabetic macular edema: systematic review and meta-analysis. Retina. 2015;35(9):1719-1725.
1. Al-wesabi, Muneer. (2012). The Role of Quality Systems in Improving the Performance of Healthcare Facilities in Yemen: A Case Study of the 48 Model Hospital. https://doi.org/10.13140/RG.2.2.12720.32009
2. Al-wesabi, Muneer. (2017). The Effect of Health Human Resources Development on the Efficacy of Applying Accreditation Standards in Yemeni Hospitals: A Field Study. https://doi.org/10.13140/RG.2.2.28658.67527
3. Al-Wesabi, M., & Shamlan, M. (2022). The Effect of Applying Infection Prevention and Control Standards in Sana’a Governorate Hospitals at the Level of Reducing the Spread of Diseases and Epidemics. Journal of 21 September University for Medical and Applied Sciences, 1(1). https://doi.org/10.65693/masj.2022.v1i1.17
4. Alyahawi, A., Al-Wesabi, M., & ALKaf, A. (2022). Antimicrobial susceptibility of Acinetobacter clinical isolates among ICU Patients in Sana’a City, Yemen. Journal of 21 September University for Medical and Applied Sciences, 1(1). https://doi.org/10.65693/masj.2022.v1i1.14
5. Alyahawi, A., & Al-Wesabi, M. (2018). A study of medication use within insured patients with chronic diseases. Institutional Repository for Scientific Scholarship at 21 September University for Medical and Applied Sciences, 1(1), 72273-72281.
Measar, M., & Al-Hoothi, E. (2023). Giant Cerebral Cavernoma: A Case Study. Journal of 21 September University for Medical and Applied Sciences, 2(1). https://doi.org/10.65693/masj.2023.v2i1.21
Taresh, N., Alakhlee, H., Al-Refai, B., & Labib, A. (2023). Effect of Pulse Steroid Therapy on Visual Acuity and Fundus Picture in Cases of Vogt Koyanagi Harada Syndrome in Yemen: Case Series Study. Journal of 21 September University for Medical and Applied Sciences, 2(1), 9-16. https://doi.org/10.65693/masj.2023.v2i1.22
Abuarij, M., & Al Qtwani, A. (2023). Efficacy of Oral Isotretinoin in Combination with Desloratadine in the Treatment of Acne Vulgaris at Al-Thawrah General Hospital, Sana’a, Yemen . Journal of 21 September University for Medical and Applied Sciences, 2(1), 17-30. https://doi.org/10.65693/masj.2023.v2i1.23
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 نبيل عبدالغني طارش، أحمد الشاحذي وآخرون (المؤلف)
This work is licensed under a Creative Commons Attribution 4.0 International License.
